The British pharmaceutical behemoth, AstraZeneca, is engaged in talks with its American counterpart, Bristol-Myers Squibb, concerning a prospective merger. Should the agreement be finalized, the newly amalgamated entity could boast a market valuation surpassing $400 billion, possibly ranking among the most significant mergers in the annals of the global pharmaceutical sector. At present, the two entities have initiated preliminary discussions about the merger; however, the realization of the deal remains in doubt, as negotiations may encounter delays or even a complete breakdown. AstraZeneca's current market value stands at roughly $264 billion, whereas Bristol-Myers Squibb's is approximately $133 billion. If the merger is accomplished, the resulting company will establish itself as the world's largest pharmaceutical group in terms of market value. Moreover, this transaction will trigger intricate regulatory challenges, with the U.S. Federal Trade Commission, the UK's Competition and Markets Authority, and the European Commission all anticipated to partake in the review process.